SARAH K TASIAN
Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Hematology-Oncology PHILADELPHIA, PA NPI 1013027077
Browse related groups: Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Hematology-Oncology PA JAZZ PHARMACEUTICALS INC. All categories
General Payments — all program years on this page
$73,546.09
- Category: General Payments
- Program years: PY2018–2024
- Record count: 24
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $28,282.11 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $27,489.00 | 3 |
| Travel and Lodging | $518.39 | 3 |
| Food and Beverage | $274.72 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $17,177.71 | 4 |
| Amgen Inc. | $10,419.40 | 4 |
| Acerta Pharma LLC | $685.00 | 1 |
By program year
Records — PY2024 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1105215655 | AstraZeneca Pharmaceuticals LP | $685.00 | 01/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1116171029 | Amgen Inc. | $58.11 | 05/29/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1116171036 | Amgen Inc. | $10,304.00 | 05/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1116171042 | Amgen Inc. | $15.28 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1116171050 | Amgen Inc. | $42.01 | 05/29/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1150194981 | JAZZ PHARMACEUTICALS INC. | $16,500.00 | 06/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1150194983 | JAZZ PHARMACEUTICALS INC. | $418.27 | 06/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1150194985 | JAZZ PHARMACEUTICALS INC. | $116.01 | 05/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150194987 | JAZZ PHARMACEUTICALS INC. | $143.43 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.